Wave Eye Scouting 2020 Sipu will be Guo Xiaoyun: China's pharmaceutical and health industry under the upgrading of investment.

On August 12, the Health Industry Capital Summit kicked off at the Boao Forum for Asia Hotel in Hainan, with the opening of the 2020 China Health Industry Ecological Conference.
the summit was organized by Zhongkang Information, CITIC Securities and Guosheng Securities.
held a six-day conference on the theme of "Day by Day - A New Era of Health Management for the Full Life Cycle".
As the conference's in-depth cooperative media, Sina Pharmaceuticals (micro-signal: sinayiyao) full special report, special topics, micro-blogs, WeChat synchronous pictures, for the attention of the guests of this industry event to bring a visual feast in person, we will be the first time to package the conference dry goods hard goods presented to the audience.
The following is part of guo Xiaoyun's speech for Zhongkang Information Industry Capital Research Center: From a long-term perspective of China's pharmaceutical and health industry under the protection of investment opportunities, Guo Xiaoyun pointed out that the speed of medical reform approval, the entire slow disease population increase or expenditure affect the entire manufacturing industry, now generic drugs and with the volume of procurement to bring about an increase in concentration, some synchronized generic drugs because of the sequence of suppliers, but also can bring the advantages of capacity quality or cost.
products are the future of competition, can be said to be in a starting line, the future of chemical drugs is a large share of China.
chinese medicine market, we believe that pharmacies still have a collection of channels, as well as consumer-centered treatment of the large single product trend, medical device market growth faster than medicine.
then look at medical services, medical services listed companies are also a chain of medical services, there is a third-party testing market.
is now innovative drugs, domestic innovative drugs this development is not said to be a great driver.
also have the opportunity in CDMO, in the future, if the future of domestic innovative drugs outsourcing, will bring new incremental market.
The pharmaceutical retail industry as a whole is a prescription outflow in the long run, but from this point of view, the progress of this prescription outflow is not too obvious, we expect the next three to five years to affect the pharmaceutical industry or the retail line."
specific to investment opportunities, with the rapid development of globalization, China has entered a period of rapid development in the international market beginning in 2015.
, we see faster commercialization, and traditional enterprises are gradually transforming.
in the area of generic drugs, generic drugs because the 4 plus 7 includes the current collection, the price of rapid decline, the future is more subsidy costs, subsidy costs of API accounted for a very large about 50%.
In the field of consumer health, the Chinese market in the world, including OTC like health care products growth is relatively fast, so the current brand strength, some market segments in the future advantages of the field, traditional Chinese medicine enterprises will have a great growth in the future.
In the field of gene therapy, our pharmaceutical companies are focused on the treatment of diseases, but from early screening of tumors to diagnosis, how to pre-position this entire health management, the future of the largest potential market cap companies may not necessarily make innovative drugs for the company, it can make the whole do particularly well."
include the likes of GE, which is the future of chronic diseases and tumor pre-market.
addition, high-end medical devices in devices, chronic diseases related to some household medications are also driven by consumption of rapid growth.
, many companies are not starting with API innovation, but starting with methods.
you can see that the income of large molecules is still the past generic drugs, but innovative drugs are the future growth point.
.